<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39351379</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2312-0541</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>ERJ open research</Title><ISOAbbreviation>ERJ Open Res</ISOAbbreviation></Journal><ArticleTitle>1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">00474-2024</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/23120541.00474-2024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) 1 year after discharge.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies (Post-hospitalisation COVID-19 and the International Severe Acute Respiratory and emerging Infection Consortium). HRQoL, assessed by the EuroQol-Five Dimensions-Five Levels utility index (EQ-5D-5L UI), pre-hospital and 1 year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient-reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Of the 1888 participants included in the primary analysis, 1149 received corticosteroids. There was no between-group difference in EQ-5D-5L UI at 1 year (mean difference 0.004, 95% CI -0.026-0.034). A similar reduction in EQ-5D-5L UI was seen at 1 year between corticosteroid exposed and nonexposed groups (mean&#xb1;sd change -0.12&#xb1;0.22 <i>versus</i> -0.11&#xb1;0.22). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a cohort of 109&#x2009;318 patients admitted to hospital with COVID-19, EQ-5D-5L UI at 1 year remained similar between the two groups.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL 1 year after hospital discharge. Treatments to address the persistent reduction in HRQoL are urgently needed.</AbstractText><CopyrightInformation>Copyright &#xa9;The authors 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leavy</LastName><ForeName>Olivia C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-0195-0812</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Ewen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lone</LastName><ForeName>Nazir I</ForeName><Initials>NI</Initials><Identifier Source="ORCID">0000-0003-2707-2779</Identifier><AffiliationInfo><Affiliation>The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Roslin Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Docherty</LastName><ForeName>Annemarie B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elneima</LastName><ForeName>Omer</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2480-8840</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greening</LastName><ForeName>Neil J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-0453-7529</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Victoria Claire</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houchen-Wolloff</LastName><ForeName>Linzy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Therapy Department, University Hospitals of Leicester, NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAuley</LastName><ForeName>Hamish J C</ForeName><Initials>HJC</Initials><Identifier Source="ORCID">0000-0001-8997-0764</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Ruth M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sereno</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shikotra</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singapuri</LastName><ForeName>Amisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aul</LastName><ForeName>Raminder</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St George's University Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beirne</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolton</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-9578-2249</Identifier><AffiliationInfo><Affiliation>University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeremy S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Gourab</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHS Lothian, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diar Bakerly</LastName><ForeName>Nawar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Manchester Metropolitan University, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Salford Royal NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Easom</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infection Research Group, Hull University Teaching Hospitals, Hull, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Hull, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Echevarria</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuld</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Cambridge Clinical Research Facility, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Nick</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6863-585X</Identifier><AffiliationInfo><Affiliation>Lane Fox Respiratory Service, Guy's and St Thomas NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurst</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-7246-6040</Identifier><AffiliationInfo><Affiliation>University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6308-6014</Identifier><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Southampton Biomedical Research Centre, University Hospitals Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parekh</LastName><ForeName>Dhruv</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1508-8362</Identifier><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeffer</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Najib M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAMS Oxford Institute, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowland-Jones</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Teaching NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ajay M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Kings College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kings College London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wootton</LastName><ForeName>Dan G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jolley</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3538-2451</Identifier><AffiliationInfo><Affiliation>Kings College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kings College London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>A A Roger</ForeName><Initials>AAR</Initials><Identifier Source="ORCID">0000-0002-0717-4551</Identifier><AffiliationInfo><Affiliation>University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Teaching NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalder</LastName><ForeName>Trudie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London and Maudsley NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Melanie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Soyza</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8566-0344</Identifier><AffiliationInfo><Affiliation>Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Newcastle upon Tyne Teaching Hospitals Trust, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geddes</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhalf</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The CRUK Liverpool Experimental Cancer Medicine Centre, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heller</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Luke</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2822-210X</Identifier><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8054-2293</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lungs for Living Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>R Gisli</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham and the University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Will D-C</ForeName><Initials>WD</Initials><Identifier Source="ORCID">0000-0002-3782-659X</Identifier><AffiliationInfo><Affiliation>Royal Brompton and Harefield Clinical Group, Guy's and St Thomas NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHLI, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>Gerry P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Openshaw</LastName><ForeName>Peter J M</ForeName><Initials>PJM</Initials><Identifier Source="ORCID">0000-0002-7220-2555</Identifier><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7307-169X</Identifier><AffiliationInfo><Affiliation>UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ILD Service, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowland</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Janet T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semple</LastName><ForeName>Malcolm G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0001-9700-0418</Identifier><AffiliationInfo><Affiliation>NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sally J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-9834-0366</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toshner</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3969-6143</Identifier><AffiliationInfo><Affiliation>NIHR Cambridge Clinical Research Facility, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge NIHR BRC, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Keir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hywel Dda University Health Board, Wales, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Swansea, Wales, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Innovation Wales, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaney</LastName><ForeName>Liam G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Belfast Health and Social Care Trust, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briggs</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorpe</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quint</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0003-0149-4869</Identifier><AffiliationInfo><Affiliation>NHLI, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalmers</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Ling-Pei</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Human Immunology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horsley</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1828-0058</Identifier><AffiliationInfo><Affiliation>Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester University NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7585-4743</Identifier><AffiliationInfo><Affiliation>Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, University College London Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poinasamy</LastName><ForeName>Krisnah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Asthma and Lung UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Betty</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1239-9608</Identifier><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radcliffe Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wain</LastName><ForeName>Louise V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0003-4951-1867</Identifier><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brightling</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Rachael A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-1667-868X</Identifier><AffiliationInfo><Affiliation>The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals of Leicester NHS Trust, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ERJ Open Res</MedlineTA><NlmUniqueID>101671641</NlmUniqueID><ISSNLinking>2312-0541</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflict of interest: O.C. Leavy declares that their institute received joint funding from UKRI and NIHR (MR/V027859/1 and COV0319) to complete this work. A.B. Docherty declares that they were awarded funding from a Wellcome Clinical Research Career Development Fellowship (216606/Z/19/Z) to complete this work. A Sheikh declares that their institute was awarded grant funding from NIHR and UKRI to complete this work; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca's Thrombotic Thrombocytopenic Taskforce; and leadership or fiduciary roles for UK and Scottish Government COVID-19 advisory groups. C.E. Bolton declares that their institute received grant funding from NIHR/UKRI and NIHR to complete this work; and their institute received grant funding from Nottingham Hospitals Charity and University of Nottingham. G. Choudhury declares funding from GlaxoSmithKline and AstraZeneca; received honoraria for delivering talks from GSK, AZ, Chiesi and BI; participation on a Data Safety Monitoring Board or Advisory Board as Chair on the Act on COPD Programme for AZ in Scotland; and a leadership or fiduciary role as Chair for the Lothian Respiratory Managed Clinical Network. N.D. Bakerly declares they have received nonrestrictive educational grants from Chiesi, AZ and Teva for attending conferences; honoraria from Teva, AZ and GSK; support for attending meetings and/or travel from Chiesi and AZ; participation on a Data Safety Monitoring Board or Advisory Board for Teva; and receipt of equipment from Global Access Diagnostics (previously Mologic Inc). A. Shikotra declares that their institute was awarded joint funding from UKRI and the NIHR (MR/V027859/1 and COV0319) to complete this work. R. Aul declares lecture fees and support for attending a meeting from Boehringer Ingelheim. C. Echevarria declares a grant from GSK. J.R. Hurst declares funding from AstraZeneca; consulting fees from AstraZeneca and GSK; payment for lectures and presentations from AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi and Takeda; support for attending meetings and/or travel from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca; and receipt of equipment from Nonin. M. Jones declares funding from the MRC to complete this work; funding from the MRC, British Lung Foundation and Boehringer Ingelheim; consulting fees from Skyhawk Therapeutics; and a leadership or fiduciary role in the AAIR Charity Scientific Committee. P. Pfeffer declares funding from NIHR. S. Rowland-Jones declares that their institute received funding from UKRI to complete this work; and their institute received funding from NIHR Sheffield Biomedical Research centre, Bill and Melinda Gates Foundation, UKRI (MRC) and EDCTP. D. Parekh declares funding from NIHR and MRC; and a leadership or fiduciary role for the Faculty of Intensive Care Medicine Board. A.A.R. Thompson declares that their institute was awarded a fellowship from the British Heart Foundation, and grant funding from Heart Research UK and the National Institute for Health and Care Research; payment for lectures and presentations from Janssen-Cilag Ltd; and support for attending meetings from Janssen-Cilag Ltd. M.J. Davies declares grant funding from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca and Janssen; consulting fees from Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Sanofi; payment for speaking for Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, AstraZeneca, Amgen, Napp Pharmaceuticals and Novartis; and is an advisory board member for Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, Lexicon, Pfizer, Medtronic and ShouTi Pharma Inc., and Zealand Pharma. A. De Soyza declares that their institute was awarded grant funding from AstraZeneca, Bayer, GSK, Chiesi, Novartis and Pfizer, outside the submitted manuscript; consulting fees from AstraZeneca, Bayer, GSK, Chiesi, Novartis, Pfizer, Insmed and Gilead; payment for lectures and presentations from AstraZeneca, Bayer, GSK, Chiesi, Novartis, Pfizer, Insmed, Gilead and 30T; participation on a Data Safety Monitoring Board or Advisory Board for Bayer; and receipt of drugs from GSK outside the submitted manuscript. S. Heller declares consulting fees from NovoNordisk; and participation on a Data Safety Monitoring Board or Advisory Board for Eli Lilly with payments made to their institution. J. Jacob declares funding from Gilead, Microsoft Research and GlaxoSmithKline; consulting fees from Boehringer Ingelheim, Roche, GlaxoSmithKline and NHSX; payment for lectures and presentations received from Boehringer Ingelheim, Roche, GlaxoSmithKline and Takeda; support for attending meetings and/or travel from Boehringer Ingelheim; patents planned, issued or pending (UK patent application number 2113765.8 and UK patent application number GB2211487.0); and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim and Roche. R.G. Jenkins declares that their institute received funding from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, Nordic Biosciences, RedX and Pliant; consulting fees from AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GlaxoSmithKline, Veracyte, Resolution Therapeutics and Pliant; payment for lectures and presentations received from Boehringer Ingelheim, Chiesi, Roche, PatientMPower and AstraZeneca; payment for expert testimony from Pinsent Masons LLP; participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Galapagos and Vicore; and a leadership or fiduciary role for NuMedii and is president for Action for Pulmonary Fibrosis. W.D-C. Man declares that their institute received funding from National Institute for Health Research and NHS Accelerated Access Collaborative; and is Honorary President of the Association for Respiratory Technology and Physiology, and an associate editor of ERJ Open Research. G.P. McCann declares funding from NIHR (RP-2017-ST2-007) to complete this work; funding from the British Heart Foundation, Wellcome Trust and NIHR; and research support from Resonance Health, Circle CVi and Perspectum. S. Neubauer declares grant funding from Oxford NIHR Biomedical Research centre. P.J.M. Openshaw declares funding from UKRI-MRC/DHSC NIHR and UKRI-BEIS. M.J. Rowland declares support for attending meetings and/or travel from Novartis Pharmaceuticals; stock or stock options from Novartis Pharmaceuticals and Roche Pharmaceuticals; and is employed full time as a Senior Clinical Development Medical Director at Novartis Pharmaceuticals. J. Porter declares funding from Breathing Matters and UCL/H BRC (NIHR), and consulting fees from The Limbic. L.G. Heaney declares that their institute received funding from GSK, AstraZeneca and Roche/Genentech; payment for lectures received from AstraZeneca, Novartis, Roche/Genentech, Sanofi, Circassia, GlaxoSmithKline, Chiesi and Teva; support to travel to meetings from AstraZeneca and GSK; participation on a Data Safety Monitoring Board or Advisory Board for Novartis, Roche/Genentech, GSK, Teva and Celltrion; and funding from the NIHR (RfPB grant PB-PG-0317-20032). J.T. Scott declares funding from UKRI. M.G. Semple declares grant funding from National Institute of Health Research UK, Medical Research Council UK and Health Protection Research Unit in Emerging and Zoonotic Infections, and University of Liverpool to complete this work; participation on a Data Safety Monitoring Board or Advisory Board for Pfizer; leadership or fiduciary roles as Chair of Infectious Disease Scientific Advisory Board Integrum Scientific LLC and Director of MedEx Solutions Ltd; stock or stock options as minority owner of Integrum Scientific LLC and majority owner of MedEx Solutions Ltd; receipt of equipment, materials, drugs, medical writing, gifts or other services from Chiesi Farmaceutici SpA; and is a nonremunerated independent member of HMG UK Scientific Advisory Group for Emergencies (SAGE), COVID-19 Response (March 2020 to March 2022) and a nonremunerated independent member of HMG UK New Emerging Respiratory Virus Threats Advisory Group (NERVTAG) (2014 to July 2023). S.J. Singh declares grants or contracts from NIHR (programme grant (NIHR 202020), Wellcome Doctoral Training Programme, HTA Project Grant (NIHR 131015), NIHR DHSC/UKRI COVID-19 Rapid Response Initiative, NIHR Global Research Group (NIHR 17/63/20)), Actegy Limited and NIHR Senior Investigator; payment for presentations for GSK, Ministry of Justice, CIPLA, Sherbourne Gibbs; participation on NICE Expert Adviser Panel (long COVID), Wales Long COVID Advisory Board and NHS-E Long Covid Your Covid Recovery working group; and leadership or fiduciary roles as ATS Pulmonary Rehabilitation Assembly Chair, Clinical Lead RCP Pulmonary Rehabilitation Accreditation Scheme and Clinical Lead NACAP Audit for Pulmonary Rehabilitation. M. Toshner declares grant funding from the NIHR Cambridge BRC and NIHR HTA to complete this work; consulting fees from Janssen; support for attending meetings and/or travel from GSK and Janssen; and participation on a Data Safety Monitoring Board or Advisory Board for ComCov and FluCov. A. Horsley declares that their institute was awarded funding from UK Research and Innovation (MR/V027859/1), the National Institute of Health Research (NIHR) (COV0319) and NIHR Manchester BRC; and is Chair for the NIHR Translational Research Collaboration. M. Marks declares that their institute received joint funding from UKRI and NIHR to complete this work. K. Poinasamy declares funding from UKRI and NIHR to complete this work. A. Briggs declares consulting fees from Roche, Merck, Sanofi and GSK. J.K. Quint declares that their institute received funding from the Industrial Strategy Challenge Fund, the Medical Research Council, Health Data Research, GSK, BI, Asthma+Lung UK and AZ; and consulting fees from GlaxoSmithKline, Evidera, Chiesi, AstraZeneca and Insmed. J.D. Chalmers declares funding from AstraZeneca, Boehringer Ingelheim, Grifols, Gilead Sciences, Insmed, Genentech and GlaxoSmithKline; consulting fees from AstraZeneca, Boehringer Ingelheim, Grifols, Gilead Sciences, Insmed, Genentech, Glaxosmithkline, Antabio, Zambon and Trudell; and leadership or fiduciary roles as Chief Editor of the European Respiratory Journal and associate editor of ERJ Open Research, Chair of the British Thoracic Society Science and Research Committee, and Trustee of the British Thoracic Society. L.V. Wain declares funding from UK Research and Innovation (MR/V027859/1), GSK/Asthma+Lung UK (Professorship (C17-1)) and National Institute of Health Research (COV0319) to complete this work; funding from Orion Pharma, GSK, Genentech, AstraZeneca, Nordic Bioscience and Sysmex (OGT); consulting fees Galapagos, Boehringer Ingelheim and GSK; support for attending meetings and/or travel Genentech; participation on Advisory Board for Galapagos; leadership or fiduciary roles as an associate editor for the European Respiratory Journal, and Medical Research Council Board member and Deputy Chair. C.E. Brightling declares that their institute received grant funding from MRC/NIHR and NIHR to complete this work; their institute received grant funding from GSK, AZ, Sanofi, Regeneron, Roche, Genentech, BI, Novartis, Chiesi, 4Dpharma and Mologic; and consulting fees from GSK, AZ, Sanofi, Regeneron, Roche, Genentech, BI, Novartis, Chiesi, 4Dpharma, Mologic and Areteia. R.A. Evans declares funding from UKRI/MRC/NIHR to complete this work; funding from Wolfson Foundation and Genentech/Roche; consulting fees from AstraZeneca/Evidera; speaking fees from Boehringer and Moderna; support for attending meetings from Chiesi; and leadership or fiduciary roles as ERS Group 01.02 Pulmonary Rehabilitation and Chronic Care Secretary, and ATS Pulmonary Rehabilitation Assembly Chair. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351379</ArticleId><ArticleId IdType="pmc">PMC11440406</ArticleId><ArticleId IdType="doi">10.1183/23120541.00474-2024</ArticleId><ArticleId IdType="pii">00474-2024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Horby P, Lim WS, Emberson JR, et al. . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384: 693&#x2013;704. doi:10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637&#x2013;1645. doi:10.1016/S0140-6736(21)00676-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399: 665&#x2013;676. doi:10.1016/S0140-6736(22)00163-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00163-5</ArticleId><ArticleId IdType="pmc">PMC8830904</ArticleId><ArticleId IdType="pubmed">35151397</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022; 400: 359&#x2013;368. doi:10.1016/S0140-6736(22)01109-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01109-6</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med 2021; 9: 1275&#x2013;1287. doi:10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10: 761&#x2013;775. doi:10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. . Health outcomes in people 2&#x2005;years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022; 10: 863&#x2013;876. doi:10.1016/S2213-2600(22)00126-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. Date last accessed: 22 October 2023. Date last updated: 11 November 2021. www.nice.org.uk/guidance/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Post COVID-19 condition (Long COVID). Date last accessed: October 22, 2023. Date last updated: 7 December 2021. www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Perego E, Callard F, Stras L, et al. . Why the patient-made term &#x201c;long COVID&#x201d; is needed. Wellcome Open Research 2020; 5: 244. doi:10.12688/wellcomeopenres.16307.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16307.1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2013;146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe1;n IP, Mart&#xed; CR, Sota DP, et al. . Corticosteroids for COVID-19 symptoms and quality of life at 1&#x2005;year from admission. J Med Virol 2022; 94: 205&#x2013;210. doi:10.1002/jmv.27296</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27296</ArticleId><ArticleId IdType="pmc">PMC8662039</ArticleId><ArticleId IdType="pubmed">34436783</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins AM, Berry LR, Lorenzi E, et al. . Long-term (180-day) outcomes in critically Ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA 2023; 329: 39&#x2013;51. doi:10.1001/jama.2022.23257</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.23257</ArticleId><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference><Reference><Citation>Elneima O, McAuley HJC, Leavy OC, et al. . Cohort profile: post-hospitalisation COVID-19 study (PHOSP-COVID). Int J Epidemiol 2024; 53: dyad165. doi:10.1093/ije/dyad165</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyad165</ArticleId></ArticleIdList></Reference><Reference><Citation>International Severe Acute Respiratory and emerging Infection Consortium . COVID-19. Date last accessed: 22 August 2023. Date last updated: 2023. https://isaric.org/research/covid-19-clinical-research-resources/</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection . A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192&#x2013;e197. doi:10.1016/S1473-3099(20)30483-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing COVID-19. Date last accessed: 28 October 2023. Date last updated: 15 June 2022. www.nice.org.uk/guidance/ng191</Citation><ArticleIdList><ArticleId IdType="pubmed">34181371</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727&#x2013;1736. doi:10.1007/s11136-011-9903-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorke J, Moosavi SH, Shuldham C, et al. . Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010; 65: 21&#x2013;26. doi:10.1136/thx.2009.118521</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2009.118521</ArticleId><ArticleId IdType="pmc">PMC2795166</ArticleId><ArticleId IdType="pubmed">19996336</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellen SB, Cella DF, Webster K, et al. . Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63&#x2013;74. doi:10.1016/S0885-3924(96)00274-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0885-3924(96)00274-6</ArticleId><ArticleId IdType="pubmed">9095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Madans JH, Loeb ME, Altman BM. Measuring disability and monitoring the UN Convention on the Rights of Persons with Disabilities: the work of the Washington Group on Disability Statistics. BMC Public Health 2011; 11: Suppl. 4, S4. doi:10.1186/1471-2458-11-S4-S4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-S4-S4</ArticleId><ArticleId IdType="pmc">PMC3104217</ArticleId><ArticleId IdType="pubmed">21624190</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SJ, Morgan MD, Scott S, et al. . Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019&#x2013;1024. doi:10.1136/thx.47.12.1019</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.47.12.1019</ArticleId><ArticleId IdType="pmc">PMC1021093</ArticleId><ArticleId IdType="pubmed">1494764</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Simonsick EM, Ferrucci L, et al. . A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85&#x2013;M94. doi:10.1093/geronj/49.2.M85</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/49.2.M85</ArticleId><ArticleId IdType="pubmed">8126356</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695&#x2013;699. doi:10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SU, Ulvenes PG, &#xd8;ktedalen T, et al. . Psychometric properties of the general anxiety disorder 7-item (GAD-7) scale in a heterogeneous psychiatric sample. Front Psychol 2019; 10: 1713. doi:10.3389/fpsyg.2019.01713</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2019.01713</ArticleId><ArticleId IdType="pmc">PMC6691128</ArticleId><ArticleId IdType="pubmed">31447721</ArticleId></ArticleIdList></Reference><Reference><Citation>Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ 2019; 365: l1476. doi:10.1136/bmj.l1476</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1476</ArticleId><ArticleId IdType="pmc">PMC6454318</ArticleId><ArticleId IdType="pubmed">30967483</ArticleId></ArticleIdList></Reference><Reference><Citation>Weathers FW, Litz BT, Keane TM, et al. . 
The PTSD checklist for DSM-5 (PCL-5). Date last accessed: 5 August 2024. Date last updated: 6 December 2023. www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp</Citation></Reference><Reference><Citation>Consumer Data Research Group . Index of Multiple Deprivation (IMD). Date last accessed 5 August 2024. Date last updated: 17 July 2024. https://data.cdrc.ac.uk/dataset/index-multiple-deprivation-imd</Citation></Reference><Reference><Citation>McNamara S, Schneider PP, Love-Koh J, et al. . Quality-adjusted life expectancy norms for the English population. Value Health 2023; 26: 163&#x2013;169. doi:10.1016/j.jval.2022.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2022.07.005</ArticleId><ArticleId IdType="pubmed">35965226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan CM, Longworth L, Lord J, et al. . The EQ-5D-5&#x2005;L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax 2016; 71: 493&#x2013;500. doi:10.1136/thoraxjnl-2015-207782</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2015-207782</ArticleId><ArticleId IdType="pmc">PMC4893131</ArticleId><ArticleId IdType="pubmed">27030578</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm A, Kj&#xe6;r MN, Munch MW, et al. . Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med 2022; 48: 580&#x2013;589. doi:10.1007/s00134-022-06677-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06677-2</ArticleId><ArticleId IdType="pmc">PMC8970069</ArticleId><ArticleId IdType="pubmed">35359168</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenes Bonet D, Caguana V&#xe9;lez OA, Duran Jord&#xe0; X, et al. . Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19. J Clin Med 2023; 12: 4158. doi:10.3390/jcm12124158</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12124158</ArticleId><ArticleId IdType="pmc">PMC10299438</ArticleId><ArticleId IdType="pubmed">37373850</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, et al. . Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM 2022; 114: 865&#x2013;871. doi:10.1093/qjmed/hcab297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med 2023; 183: 554&#x2013;564. doi:10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study. BMJ 2023; 381: e074572. doi:10.1136/bmj-2022-074572</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PD, Evans RA, Tear VJ, et al. . LB1533. Impact of treatment of hospitalised COVID-19 patients with inhaled interferon beta-1a (SNG001) on long COVID symptoms: results from the SPRINTER trial. Open Forum Infect Dis 2022; 9: Suppl. 2, ofac492.1879. doi:10.1093/ofid/ofac492.1879</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac492.1879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. . Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10&#x2005;months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis 2023; 23: 1119&#x2013;1129. doi:10.1016/S1473-3099(23)00299-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshner MR, Gamble C, Baillie JK, et al. . Apixaban following discharge in hospitalised adults with COVID-19: preliminary results from a multicentre, open-label, randomised controlled platform clinical trial. medRxiv 2022; preprint [10.1101/2022.12.07.22283175].</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.07.22283175</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov . Helping alleviate the longer-term consequences of COVID-19 (HEAL-COVID). Date last updated: 23 July 2021. https://clinicaltrials.gov/study/NCT04801940/</Citation></Reference><Reference><Citation>Finnigan LEM, Cassar MP, Koziel MJ, et al. . Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. EClinicalMedicine 2023; 59: 101946. doi:10.1016/j.eclinm.2023.101946</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101946</ArticleId><ArticleId IdType="pmc">PMC10102537</ArticleId><ArticleId IdType="pubmed">37223439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasawmy M, Mu Y, Clutterbuck D, et al. . STIMULATE-ICP-CAREINEQUAL (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study protocol: defining usual care and examining inequalities in long COVID support. PLoS One 2022; 17: e0271978. doi:10.1371/journal.pone.0271978</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0271978</ArticleId><ArticleId IdType="pmc">PMC9377596</ArticleId><ArticleId IdType="pubmed">35969597</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID . The Post-hospitalisation COVID-19 study (PHOSP-COVID). Date last accessed: 3 October 2023. https://phosp.org/</Citation></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, et al. . Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine 2023; 41: 1783&#x2013;1790. doi:10.1016/j.vaccine.2023.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>